Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
AssigneeThe Rockefeller University
InventorsStephen D. Wolpe, Anthony Cerami
Life of this patent
Estimating the term…
Abstract
The present invention pertains to the novel hybridoma SDW18.1.1, hybridomas obtained from SDW18.1.1, monoclonal antibodies obtained from such hybridomas and derivatives of such monoclonal antibodies. The novel hybridomas are formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with cachectin/TNF. Diagnostic and therapeutic utilities for the monoclonal antibodies and their derivatives are proposed, and testing procedures, materials in kit form and pharmaceutical compositions are likewise set forth.
Claims2
A method of ameliorating or preventing septic shock which comprises administering to a mammalian patient suspected of having a need for such administration an effective amount of a monoclonal antibody exhibiting the characteristics of a monoclonal antibody as produced by hybridoma cell line having the identifying characteristics of A.T.C.C. Accession No. HB 9228.
Dependencies are inferred from the claim text.